Trials / Recruiting
RecruitingNCT05489289
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
A Randomized, Double-blind, Phase III Clinical Study on the Efficacy and Safety of AK104 Versus Placebo as Adjuvant Therapy for Hepatocellular Carcinoma With High Risk of Recurrence After Curative Resection
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 570 (estimated)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The efficacy and safety of AK104 as adjuvant therapy in hepatocellular carcinoma of high recurrence risk after curative resection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AK104 | Subjects will receive AK104 until disease progression or for a maximum of 16 cycles |
| BIOLOGICAL | placebo | Subjects will receive placebo until disease progression or for a maximum of 16 cycles |
Timeline
- Start date
- 2023-01-05
- Primary completion
- 2026-01-28
- Completion
- 2027-01-01
- First posted
- 2022-08-05
- Last updated
- 2025-03-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05489289. Inclusion in this directory is not an endorsement.